Celldex Therapeutics (CLDX)

What Moves the Stock

1. 01Barzolvolimab Phase 2b data readouts in chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU) - primary endpoints on itch severity and urticaria activity scores
2. 02FDA regulatory pathway clarity and potential breakthrough therapy designation for barzolvolimab in urticaria indications
3. 03Clinical trial initiation announcements for barzolvolimab expansion into additional mast cell-driven diseases (hereditary alpha tryptasemia, systemic mastocytosis)
4. 04Cash runway updates and equity financing announcements - dilution concerns vs. funding adequacy
5. 05Strategic partnership or licensing deals that validate platform technology and provide non-dilutive capital
6. 06No current commercial revenue - pre-revenue clinical-stage company
7. 07Potential future revenue from barzolvolimab in chronic urticaria (estimated peak sales $1-2B+ if approved)
8. 08Potential milestone payments and royalties from future partnerships or out-licensing deals

CLDX Chart

My Notes

• growth - High-risk, high-reward profile attracts biotech specialists, venture-style investors…
• Rising interest rates negatively impact valuation through higher discount rates applied to distant future cash flows (barzolvolimab revenues…
• Watch on earnings: Barzolvolimab Phase 2b trial enrollment completion and data readout timing (expected 2026-2027), Quarterly cash burn rate and total cash/equivalents balance - runway through key milestones, FDA feedback on regulatory pathway and potential accelerated approval eligibility.